Form 4: Bicycle Therapeutics PLC: Officer Sells Shares to Cover Tax Obligations

Alistair Milnes, Chief Operating Officer of Bicycle Therapeutics PLC, sold 967 ordinary shares to cover tax withholding obligations related to the vesting and settlement of RSUs on July 3, 2024.

Summary

• On July 3, 2024, Alistair Milnes, the Chief Operating Officer of Bicycle Therapeutics PLC, sold 967 ordinary shares of the company.
• The sale was executed to cover statutory tax withholding obligations associated with the vesting and settlement of Restricted Stock Units (RSUs).
• The shares were sold at a weighted average price of $19.64, with individual transactions ranging from $19.63 to $19.69.
• Following the transaction, Milnes directly owns 71,274 ordinary shares of Bicycle Therapeutics PLC.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The document describes a routine transaction related to tax obligations, which doesn't inherently indicate positive or negative sentiment about the company's performance.

Future Outlook

There is no future outlook provided in this document.

Industry Context

This is a routine transaction related to executive compensation and tax obligations. It is common for company officers to sell shares to cover taxes when RSUs vest. This type of transaction is closely monitored by investors for potential insights into management's view of the company's prospects, although in this case, it is explicitly stated as a 'sell to cover' transaction.

Comparison to Industry Standards

• Executive compensation practices, including the use of RSUs and subsequent 'sell to cover' transactions, are standard across publicly traded companies, particularly in the biotechnology sector.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize RSUs as part of their compensation packages, and their executives often engage in similar transactions to manage tax liabilities.
• The weighted average price of $19.64 per share can be compared to the trading prices of BCYC shares on July 3, 2024, to assess whether the sale was executed at a fair market value.

Stakeholder Impact

• The sale of shares by the COO could have a minor impact on shareholders due to the increased supply of shares in the market, but the impact is likely to be minimal given the relatively small number of shares sold.

Key Dates